Drug Profile
BXQ 350
Alternative Names: BXQ-350; SapC; SapC-DOPS; SapC-DOPS nanovesicles; Saposin C–dioleoylphosphatidylserine complexes; Sphingolipid activator protein CLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Bexion Pharmaceuticals
- Developer Bexion Pharmaceuticals; Cincinnati Children's Hospital Medical Center
- Class Antineoplastics; Phosphatidylserines; Saposins; Tumour-agnostic therapies
- Mechanism of Action Sphingomyelin phosphodiesterase stimulants; Sphingosine 1-phosphate stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Glioblastoma; Glioma; Peripheral nervous system diseases
- Preclinical CNS disorders; Viral infections
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Glioma(In adolescents, In children, In adults) in USA (IV, Infusion)
- 31 May 2023 Pharmacodynamics data from a phase I trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 31 May 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)